Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.9M Buy
+8,228
New +$2.93M 0.72% 12
2025
Q3
Sell
-1,575
Closed -$440K 573
2025
Q2
$440K Buy
+1,575
New +$446K 0.12% 306
2025
Q1
Sell
-5,929
Closed -$1.55M 605
2024
Q4
$1.55M Buy
5,929
+3,103
+110% +$921K 0.52% 22
2024
Q3
$911K Buy
+2,826
New +$924K 0.35% 62
2023
Q1
Sell
-1,982
Closed -$521K 411
2022
Q4
$521K Buy
+1,982
New +$531K 0.36% 88
2021
Q3
Sell
-3,200
Closed -$780K 319
2021
Q2
$780K Buy
+3,200
New +$787K 0.29% 79
2021
Q1
Sell
-3,300
Closed -$759K 656
2020
Q4
$759K Buy
+3,300
New +$761K 0.26% 109

Other funds holding AMGN

Bridgefront Capital's AMGN Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Amgen (AMGN) in Q1 2026: 8,228 shares worth $2.9M. The stake represents 0.72% of the portfolio and ranks #12 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in AMGN as recently as Q2 2025.

Bridgefront Capital first reported a position in AMGN in Q4 2020 and has held it in 7 quarters since. 3,130 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Bridgefront Capital held 8,228 shares of Amgen worth $2.9M as of Q1 2026.
  • Amgen was a new Bridgefront Capital position in Q1 2026.
  • Amgen made up 0.72% of Bridgefront Capital's portfolio in Q1 2026, its #12 holding.
  • Bridgefront Capital first reported a position in Amgen in Q4 2020 and has held it in 7 quarters since.
  • 3,130 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.